Actively Recruiting
Swedish Ibrance Registries Insights (SIRI)
Led by Pfizer · Updated on 2026-03-31
1500
Participants Needed
1
Research Sites
284 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The main objectives of this study are to describe patient characteristics, treatment patterns and clinical outcomes of patients receiving palbociclib in Swedish clinical practice.
CONDITIONS
Official Title
Swedish Ibrance Registries Insights (SIRI)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- One or more (≥1) filled prescription of palbociclib (ATC code: L01XE33)
- Age 18 years or older at index date
You will not qualify if you...
- None
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Pfizer Sweden
Sollentuna, Sweden
Actively Recruiting
Research Team
P
Pfizer CT.gov Call Center
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here